EUVIMEDEUVIMED entdecken
Crossref

Success and Futility Criteria for Accelerated Approval of Oncology Drugs

Dong Xi iD, Jiangtao Gou iD

Pharmaceutical Statistics · 2025

DOI: 10.1002/pst.70004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2025. Verfasst von Dong Xi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Foster City, California, USA. Hauptthemen laut MEDLINE: Drug Approval, Antineoplastic Agents, Clinical Trials as Topic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Project FrontRunner encourages development of cancer drugs for advanced or metastatic disease in an earlier clinical setting by promoting regulatory approaches such as the accelerated approval pathway. The FDA draft guideline proposes a one‐trial approach to combine accelerated approval and regular approval in a single trial to maintain efficiency. This article describes our idea of controlling Type I error for accelerated and regular approvals in the one‐trial approach. We introduce success and futility boundaries on p ‐values for accelerated approval to create three outcomes: success, RA, and futility. If success, accelerated approval can be claimed for; for RA, only regular approval (RA) is considered; if futility, we stop the trial early for futility. For both success and RA, the endpoint for regular approval can be tested with no penalty on its significance level. The proposed approach is robust to all possible values of correlation between test statistics of the endpoints for accelerated and regular approvals. This framework is flexible to allow clinical trial teams to tailor success and futility boundaries to meet clinical and regulatory needs, while maintaining the overall Type I error control in the strong sense.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalAntineoplastic AgentsClinical Trials as TopicHumansUnited States Food and Drug AdministrationUnited StatesMedical FutilityResearch DesignNeoplasmsEndpoint Determination

Stichwörter der Autor:innen

FrontRunnerType I erroraccelerated approvalone‐trial approachregular approval

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Gilead Sciences, Foster City, California, USA.
  • Villanova University, Villanova, Pennsylvania, USA.

ORCID-Profile: Dong Xi, Jiangtao Gou

Zitieren

APA

Xi, D., & Gou, J. (2025). Success and Futility Criteria for Accelerated Approval of Oncology Drugs. Pharmaceutical Statistics. https://doi.org/10.1002/pst.70004

Vancouver

Xi D, Gou J. Success and Futility Criteria for Accelerated Approval of Oncology Drugs. Pharmaceutical Statistics. 2025. doi:10.1002/pst.70004

BibTeX
@article{Xi2025,
  author = {Xi, Dong and Gou, Jiangtao},
  title = {Success and Futility Criteria for Accelerated Approval of Oncology Drugs},
  journal = {Pharmaceutical Statistics},
  year = {2025},
  doi = {10.1002/pst.70004}
}
Kostenlos starten →